Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Medicare Advantage Prior Auth Policy | …
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy N/A

    Medicare Part B Drug Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements for selected Medicare Part B drugs administered by providers under Providence Medicare Advantage Plans; affects providers seeking coverage for listed Part B medications for plan members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerProvidence Medicare Advantage Plans
    PolicyPrior Authorization Criteria for Medicare Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from Providence Medicare Advantage Plans before administering any listed Part B drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~200listed Part B medications/CPT/HCPCS entries
    6/1/2026policy effective date
    Providence MApayer
    503-574-8000provider contact
    multipleentries with post‑1/1/2026 effective dates

    Coverage Criteria and Prior Authorization Overview

    General prior authorization requirement

    Prior authorization coverage applies to the listed Part B drugs when plan approval is obtained in advance.

    General requirement: Provider obtains prior authorization from Providence Medicare Advantage Plans before administration of any listed Part B drug

    See individual drug policy links for specific clinical criteria

    If a required prior authorization is not obtained from Providence Medicare Advantage Plans before administration of a listed Part B drug, the plan may not cover the drug. Providers and ordering clinicians must secure plan approval in advance per the listed drug-specific requirements to avoid denial of coverage.

    HCPCS/CPT/Q/J Codes and Medication Listings

    Medicare Part B HCPCS/CPT Codes (selected)HCPCSCovered
    J9395Faslodex (Fulvestrant)
    J1951Fensolvi (Leuprolide acetate)
    J1572Flebogamma (Immune globulin)
    J1325Flolan, Veletri (Epoprostenol)
    J9394Fulvestrant (fresenius kabi)
    J9393Fulvestrant (teva)
    J9331Fyarro (Sirolimus protein-bound particles)
    Q5130Fylnetra (Pegfilgrastim-pbbk)
    S0132Fyremadel (Ganirelix acetate)
    J1460GamaSTAN S/D (Immune globulin)
    1–10 of 23
    1/3
    Additional Medicare Part B HCPCS/CPT CodesHCPCS
    J1460/J1560GamaSTAN S/D (Immune globulin) - combined listing
    J1561Gammaked / Gamunex-C (Immune globulin)
    J0614Grafapex (Treosulfan) - duplicate allowed for cross-reference
    Enteral Medical Nutrition CodesHCPCSCovered
    B4034Enteral formula
    B4035Enteral formula
    B4036Enteral formula
    B4104Enteral formula
    B4105Enteral formula
    B4149Enteral formula
    Medicare Part B J-Codes and Misc Medications (sample block)mixedCovered
    J9331Fyarro (Sirolimus protein-bound particles)
    Q5130Fylnetra (Pegfilgrastim-pbbk)
    S0132Fyremadel (Ganirelix acetate)
    J9210Gamifant (Emapalumab-lzsg)
    J1557Gammaplex (Immune globulin)
    J0638Ilaris (Canakinumab/pf)
    Medications (sample)HCPCSCovered
    J9395Faslodex (Fulvestrant)
    J1951Fensolvi (Leuprolide acetate)
    J1572Flebogamma (Immune globulin)
    J1325Flolan, Veletri (Epoprostenol)
    J9394Fulvestrant (fresenius kabi)
    J9393Fulvestrant (teva)
    Medications (sample)HCPCSCovered
    J9331Fyarro (Sirolimus protein-bound particles)
    Q5130Fylnetra (Pegfilgrastim-pbbk)
    S0132Fyremadel (Ganirelix acetate)
    J1460/J1560GamaSTAN S/D (Immune globulin)
    J9210Gamifant (Emapalumab-lzsg)
    J1569Gammagard Liquid (Immune globulin)
    Enteral Medical Nutrition (sample)HCPCSCovered
    B4034Enteral formula
    B4035Enteral formula
    B4036Enteral formula
    B4104Enteral formula
    B4105Enteral formula
    B4149Enteral formula
    Medicare Part B HCPCS/J Codes and Medications (comprehensive selections)HCPCSCovered
    J1566Gammagard S-D (Immune globulin)
    J1561Gammaked / Gamunex-C (Immune globulin)
    J1557Gammaplex (Immune globulin)
    J1554Asceniv (Immune globulin)
    J1552Alyglo (Immune globulin)
    J1599Immune globulin, intravenous, non-lyophilized, NOS
    J0614Grafapex (Treosulfan)
    J0614Grafapex (Treosulfan) - duplicate for emphasis
    J9179Halaven (Eribulin mesylate)
    J1411Hemgenix (Etranacogene dezaparvovec-drlb)
    1–10 of 25
    1/3

    Provider Actions, Authorization Steps, and Billing Notes

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the Medicare Part B drugs listed below. Providers must obtain approval before administration/claim submission; claims for listed HCPCS/CPT/Q/C codes submitted without an approved prior authorization may be denied or not covered.

    • Provider contact for prior authorization: Providence Medicare Advantage Plans at 503-574-8000 or 1-800-603-2340. TTY: 711. Hours: daily 8 a.m.–8 p.m. PT (seasonal weekend closures Apr 1–Sep 30).
    • This list includes many specialty injectable and infusible drugs — utilization management (including prior authorization) applies to these therapies to ensure appropriate use and site-of-care considerations.
    • Failure to obtain required prior authorization can result in claim denials or non-coverage; obtain PA before treatment to avoid member liability.
    Note

    Medicare Part B Drugs Requiring Prior Authorization (sample)

    Sample entries (each drug has a policy criteria link — click to view the full clinical criteria and any effective date notes). Use the linked policy for the specific medical necessity and documentation requirements for initial and continuation therapy.

    Background and Purpose

    Prior authorization is used to ensure appropriate use of certain medications — particularly specialty drugs administered by providers (injections or infusions). Requiring plan approval before administration helps the health plan confirm that the drug is medically necessary, used in the correct clinical circumstances, and procured and billed according to Providence Medicare Advantage Plans policies.

    Key Definitions

    Prior authorization — definition and key points
    DefinitionApproval from the health plan obtained before the plan will agree to cover a specified medication or service.
    PurposeEnsures appropriate use of certain medications (including specialty drugs administered by providers) by requiring plan approval before coverage.
    ApplicabilityRequired for certain Medicare Part B–eligible drugs listed in this policy; providers (or physicians) must obtain authorization before administration.
    Consequence of no authorizationIf prior authorization is not obtained, the plan may not cover the drug.
    How to requestProviders should contact Providence Medicare Advantage Plans to request prior authorization (see policy contact information).

    Site-of-Care Notes

    Note

    Infusion/administration site: prior authorization applies

    Drugs administered by providers (injectable or infused) are subject to prior authorization; see the individual drug policy links for site-of-care guidance (infusion center or other settings).

    • The policy directs providers to individual drug policies for site-of-care specifics.
    Policy Summary
    PayerProvidence Medicare Advantage Plans
    PolicyPrior Authorization Criteria for Medicare Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from Providence Medicare Advantage Plans before administering any listed Part B drug.
    SourceLink
    On This Page
    Coverage Criteria and Prior Authorization OverviewHCPCS/CPT/Q/J Codes and Medication ListingsProvider Actions, Authorization Steps, and Billing NotesBackground and PurposeKey DefinitionsSite-of-Care Notes
    • Q2055 — Abecma (Idecabtagene vicleucel) — Click to view
    • J9264 — Abraxane (Paclitaxel protein-bound particles) — Click to view
    • J3262 — Actemra (Tocilizumab) — Click to view
    • J0791 — Adakveo (Crizanlizumab-tmca) — Click to view
    • J9042 — Adcetris (Brentuximab vedotin) — Click to view
    Documentation Required

    Documentation and Policy Links Provided per Drug

    Documentation and direct policy links are provided for each listed drug. Before submitting a PA request, consult the drug-specific policy ("Click to view") for required clinical documentation, code(s), and any Effective Date that impacts when the PA requirement starts.

    • Each listed entry includes HCPCS/CPT/Q-code, medication name, and a "Click to view" link to the policy criteria.
    • Some entries include an "Effective Date (if after 1/1/2026)" annotation — consult the drug policy for the exact effective date when the PA requirement begins.
    Note

    Utilization Management Note

    Specialty injectables and infusible drugs on this list may also be subject to additional utilization management (e.g., quantity limits, site-of-care review, step requirements). Review the specific drug policy for any utilization management rules that apply.

    • Utilization management may include: site-of-care review, quantity limits, medical necessity criteria, and requirement to use preferred product when applicable.
    • If utilization management rules exist (including step therapy), they will be documented on the drug-specific "Click to view" policy page.
    Step Therapy

    Step Therapy (see individual drug policies)

    Step therapy: No universal step therapy rules are specified in this section excerpt. If a drug requires step therapy, the drug-specific policy (linked via "Click to view") will state the required prior steps and alternatives.

    • Consult each drug's policy link for any step-therapy requirements or exceptions.